Galecto (Group)

	Start	2020-01-07 existent
	End	2020-01-07 renamed (announced)
	Predecessor	Galecto Biotech AB
	Industry	LOXL-2 inhibitor (Lysyl Oxidase-Like type 2 inhibitor)
	Industry 2	galectin-3 inhibitor
	Person	Schambye, Hans T. (Galecto Biotech 201111– CEO before OncoNOx + Reception + Gastrotech + Maxygen + ProFound Pharma)
	Person 2	Freve, Jonathan (Galecto 202010 CFO)

	Region	København (Copenhagen)
	Country	Denmark

Basic data	Employees	n. a.


		Record changed: 2024-02-12

Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x200px

More documents for Galecto (Group)

[1] Galecto, Inc.. (10/28/20). "Press Release: Galecto Announces Pricing of Initial Public Offering". Boston, MA & Copenhagen....
[2] Galecto, Inc.. (9/25/20). "Press Release: Galecto Raises $64 Million to Accelerate Development of Clinical Pipeline". Boston, MA & Copenhagen....
[3] Galecto Biotech AB. (1/7/20). "Press Release: Galecto and PharmAkea Merge to Create Strong Clinical-stage Company Developing First-in-Class Therapeutics in Fibrosis and Cancer". San Diego, CA & Copenhagen....
[4] Seventure Partners. (2/20/19). "Press Release: Seventure Keeps up Pace of Its International Microbiome Investments, Closing Four Deals Spanning Seed to Series C". Paris....
[5] Galecto Biotech AB. (10/26/18). "Press Release: Galecto Biotech Raises €79 Million in Series C Financing Co-Led by Ysios Capital and OrbiMed to Advance Galectin Inhibitor to Late-Stage Clinical Development". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]